loader2
Partner With Us NRI

Glaxosmithkline Pharmaceuticals Ltd share Price Today

Company details

2,639.95
2,760.00
1,377.25
2,760.00
6M Return 53.20%
1Y Return 90.18%
Mkt Cap.(Cr) 44,974.75
Volume 123,918
Div Yield 1.20%
OI
-
OI Chg %
-
Volume 123,918

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue for the quarter came in at Rs 911 crore recorded a growth of 16%.
  • Profit before exceptional items and tax for the quarter at Rs 266 crore recorded a growth of 51% with EBITDA margins at 28%.

FY24 Financial Highlights:

  • The full year reported revenue was at Rs 3,407 crore, a growth of 6%, demonstrating positive growth driven by a strong volume recovery thereby offsetting NLEM (National List of Essential Medicines) impact.
  • Profit before exceptional items and tax for the year at Rs 953 crore recorded a growth of 14% with EBITDA at 26.4% up by 150 bps.

Commenting on the results for Q4 and FY 2023-24, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “For Q4, we delivered a strong double-digit growth and a robust performance across our General Medicines, Specialty and Vaccines portfolio. Our General Medicines portfolio recorded strong double-digit growth of 12% for the quarter, driven by key focus brands Augmentin, Ceftum and Calpol. Despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share.

Specialty portfolio led by Nucala and Trelegy has accelerated the momentum with highest patient recruitment in Q4.

For the vaccines business, over the last two quarters, we have seen a steady upswing in both adult and paediatric segments. This business delivered a Q4 growth of 35%. We continue to build on the momentum generated with the launch of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) as we drive expansion of the Adult Immunisation category in India with innovative go-to-market (GTM) strategies."

Result PDF

View Other Company Results

Glaxosmithkline Pharmaceuticals Ltd shares SWOT Analysis

Strengths (9)

  • Stock passes majority of CANSLIM Investment criteria
  • Strong Momentum: Price above short, medium and long term moving averages
  • New 52 week high today

Weakness (3)

  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years
  • Annual net profit declining for last 2 years

Opportunity (2)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • RSI indicating price strength

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 2,729.9
R2 2,805.0
R3 2,850.0
Pivot

2,684.93

S1 2,609.9
S2 2,564.9
S3 2,489.8
EMA SMA
2,483.2
2,301.2
2,160.3
1,971.3
2,504.8
2,201.1
2,176.0
1,912.3
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-17 1378.65 80615 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-17 1378.65 11841 BSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-10-17 1378.65 80615 BSE
Name Category Shares
GLAXO GROUP LIMITED PROMOTER 35.99%
GLAXOSMITHKLINE PTE LIMITED PROMOTER 28.1%
ESKAYLAB LIMITED PROMOTER 6.94%
BURROUGHS WELLCOME INTERNATIONAL LIMITED PROMOTER 3.97%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Glaxosmithkline Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) Glaxosmithkline Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 2,654.85 1,516.00 1,564.75 4,588.60 1,109.55
% Change -1.70 0.34 1.31 -0.11 1.75
Mcap Cr 44,974.75 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 3,453.71 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 589.96 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 68.73 36.34 29.68 76.10 28.94
1 Year Return 90.18 53.43 59.42 31.57 114.34
ROCE 44.97 16.79 14.76 19.30 16.25
ROE 37.32 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,777.64 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,088.77 -1,030.79
LAST 3M 113,155.52 -39,495.50
LAST 6M 184,812.44 -13,263.60
LAST 12M 291,038.85 99,015.20
GlaxoSmithKline Pharmaceuticals Limited - Loss of Share Certificates

Jun 14, 2024 l NSE Announcement

GlaxoSmithKline Pharmaceuticals Limited - Updates

Jun 12, 2024 l NSE Announcement

GlaxoSmithKline Pharmaceuticals Limited - Updates

Jun 11, 2024 l NSE Announcement

Date Action Type Ratio
May 31, 2024 Dividend 320
Jun 30, 2023 Dividend 320
Jul 07, 2022 Dividend 300

Glaxosmithkline Pharmaceuticals Ltd Information

Stock PE (TTM)
68.73
Promoter Holding
75%
Book Value
104.9337
ROCE
44.97%
ROE
37.32%
Description
  • GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

    GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.

Registered Address

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24959595
Email : askus:gsk.com; ajay.a.nadkarni:gsk.com
Website : http://www.gsk-india.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500660
NSE Code : GLAXO
Book Closure Date (Month) :
BSE Group : A
ISIN : INE159A01016

FAQ’s on Glaxosmithkline Pharmaceuticals Ltd Shares

You can buy Glaxosmithkline Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glaxosmithkline Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:57 PM the closing price of Glaxosmithkline Pharmaceuticals Ltd was Rs.2,654.85.

The latest PE ratio of Glaxosmithkline Pharmaceuticals Ltd as of Jun 14, 2024 03:57 PM is 68.73

The latest PB ratio of Glaxosmithkline Pharmaceuticals Ltd as of Jun 14, 2024 03:57 PM is 0.04

The 52-week high of Glaxosmithkline Pharmaceuticals Ltd share price is Rs. 2,760.00 while the 52-week low is Rs. 1,377.25

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:57 PM, the market cap of Glaxosmithkline Pharmaceuticals Ltd stood at Rs. 44,974.75.

Download App

Download Our App

Play Store App Store
market app